Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 53, Issue 15, Pages 5886-5889Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm100380k
Keywords
-
Categories
Funding
- Apotex Incorporation, Canada
Ask authors/readers for more resources
This report presents that Deferiprone, the only clinically used 3-hydroxypyridin-4-one (HPO), is able to penetrate the blood-brain barrier (BBB) in guinea pigs, whereas its glucosylated analogue is unable to do so. This finding is contrary to published information suggesting that the glucosylation of HPOs is a viable means of enhancing the brain uptake of this group of compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available